1
|
De Luca F, Roda E, Rossi P, Bottone MG. Medicinal Mushrooms in Metastatic Breast Cancer: What Is Their Therapeutic Potential as Adjuvant in Clinical Settings? Curr Issues Mol Biol 2024; 46:7577-7591. [PMID: 39057091 PMCID: PMC11276109 DOI: 10.3390/cimb46070450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2024] [Revised: 07/07/2024] [Accepted: 07/15/2024] [Indexed: 07/28/2024] Open
Abstract
Breast cancer (BC) is the most commonly diagnosed tumor, remaining one of the leading causes of morbidity and mortality in females worldwide, with the highest rates in Western countries. Among metastatic BC (MBC), triple-negative breast cancer (TNBC) is characterized by the lack of expression of specific receptors, and differs from other subgroups of BC for its increased growth and fast spreading, with reduced treatment possibilities and a worse outcome. Actually, MBC patients are extremely prone to metastasis and consequent relapses, which affect distant target organs (e.g., brain, lung, bone and liver). Hence, the comprehension of biological mechanisms underlying the BC metastatization process is a key requirement to conceive/set up innovative medicinal strategies, with the goal to achieve long-lasting therapeutic efficacy, reducing adverse effects, and also ameliorating Quality of Life (QoL). Bioactive metabolites isolated from medicinal mushrooms (MMs) used as a supportive treatment, combined with conventional oncology, have recently gained wide interest. In fact, mounting evidence has revealed their peculiar promising immunomodulatory, anti-inflammatory and anticancer activities, even though these effects have to be further clarified. Among the group of most promising MMs are Lentinula edodes, Grifola frondosa, Ganoderma lucidum, Ophiocordyceps sinensis and Agaricus blazei, which are already employed in conventional cancer protocols in Asia and China. Recently, a growing number of studies have focused on the pharmacology and feasibility of MM-derived bioactive compounds as a novel valuable approach to propose an effective adjuvant therapy for MBC patients' management. In this review, we summarized the current state of knowledge on the abovementioned MM-derived bioactive compounds and their therapeutic potential in clinical settings.
Collapse
Affiliation(s)
- Fabrizio De Luca
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (P.R.)
| | - Elisa Roda
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri, IRCCS Pavia, 27100 Pavia, Italy;
| | - Paola Rossi
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (P.R.)
| | - Maria Grazia Bottone
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (P.R.)
| |
Collapse
|
2
|
Gaiaschi L, De Luca F, Roda E, Ferrari B, Casali C, Inguscio CR, Gola F, Pelloni E, Savino E, Ravera M, Rossi P, Bottone MG. A Phyto-mycotherapeutic Supplement, Namely Ganostile, as Effective Adjuvant in Brain Cancer Management: An In Vitro Study Using U251 Human Glioblastoma Cell Line. Int J Mol Sci 2024; 25:6204. [PMID: 38892392 PMCID: PMC11172483 DOI: 10.3390/ijms25116204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 05/28/2024] [Accepted: 05/31/2024] [Indexed: 06/21/2024] Open
Abstract
The current standard oncotherapy for glioblastoma is limited by several adverse side effects, leading to a short-term patient survival rate paralleled by a worsening quality of life (QoL). Recently, Complementary and Integrative Medicine's (CIM) innovative approaches have shown positive impacts in terms of better response to treatment, side effect reduction, and QoL improvement. In particular, promising potential in cancer therapy has been found in compounds coming from phyto- and mycotherapy. The objective of this study was to demonstrate the beneficial effects of a new phyto-mycotherapy supplement, named Ganostile, in the human glioblastoma cell line U251, in combination with chemotherapeutic agents, i.e., Cisplatin and a new platinum-based prodrug. Choosing a supplement dosage that mimicked oral supplementation in humans (about 1 g/day), through in vitro assays, microscopy, and cytometric analysis, it has emerged that the cells, after 48hr continuous exposure to Ganostile in combination with the chemical compounds, showed a higher mortality and a lower proliferation rate than the samples subjected to the different treatments administered individually. In conclusion, our data support the use of Ganostile in integrative oncology protocols as a promising adjuvant able to amplify conventional and new drug effects and also reducing resistance mechanisms often observed in brain tumors.
Collapse
Affiliation(s)
- Ludovica Gaiaschi
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Fabrizio De Luca
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Elisa Roda
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy
| | - Beatrice Ferrari
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Claudio Casali
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Chiara Rita Inguscio
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Federica Gola
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Enrico Pelloni
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Elena Savino
- Department of Earth and Environmental Sciences (DSTA), University of Pavia, Via Ferrata 1, 27100 Pavia, Italy
| | - Mauro Ravera
- Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale "A. Avogadro", Viale Teresa Michel 11, 15121 Alessandria, Italy
| | - Paola Rossi
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| | - Maria Grazia Bottone
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy
| |
Collapse
|
3
|
Gariboldi MB, Marras E, Ferrario N, Vivona V, Prini P, Vignati F, Perletti G. Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer. Int J Mol Sci 2023; 24:10120. [PMID: 37373268 DOI: 10.3390/ijms241210120] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 06/09/2023] [Accepted: 06/11/2023] [Indexed: 06/29/2023] Open
Abstract
Edible/medicinal mushrooms have been traditionally used in Asian countries either in the cuisine or as dietary supplements and nutraceuticals. In recent decades, they have aroused increasing attention in Europe as well, due to their health and nutritional benefits. In particular, among the different pharmacological activities reported (antibacterial, anti-inflammatory, antioxidative, antiviral, immunomodulating, antidiabetic, etc.), edible/medicinal mushrooms have been shown to exert in vitro and in vivo anticancer effects on several kinds of tumors, including breast cancer. In this article, we reviewed mushrooms showing antineoplastic activity again breast cancer cells, especially focusing on the possible bioactive compounds involved and their mechanisms of action. In particular, the following mushrooms have been considered: Agaricus bisporus, Antrodia cinnamomea, Cordyceps sinensis, Cordyceps militaris, Coriolus versicolor, Ganoderma lucidum, Grifola frondosa, Lentinula edodes, and Pleurotus ostreatus. We also report insights into the relationship between dietary consumption of edible mushrooms and breast cancer risk, and the results of clinical studies and meta-analyses focusing on the effects of fungal extracts on breast cancer patients.
Collapse
Affiliation(s)
- Marzia Bruna Gariboldi
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Emanuela Marras
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Nicole Ferrario
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Veronica Vivona
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Pamela Prini
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Francesca Vignati
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| | - Gianpaolo Perletti
- Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy
| |
Collapse
|
4
|
Gaiaschi L, Favaron C, Casali C, Gola F, De Luca F, Ravera M, Roda E, Rossi P, Bottone MG. Study on the activation of cell death mechanisms: in search of new therapeutic targets in glioblastoma multiforme. Apoptosis 2023:10.1007/s10495-023-01857-x. [PMID: 37244884 DOI: 10.1007/s10495-023-01857-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2023] [Indexed: 05/29/2023]
Abstract
Malignant primary brain tumors remain among the most difficult cancers to treat, in particular, Glioblastoma Multiforme (GBM) is the deadliest brain tumor. The standard therapies currently used are not efficient enough in improving patients' survival and quality of life. Cisplatin (CDDP), a platinum-based drug, has shown efficacy against different solid neoplasms, but it is also associated to different forms of off-target toxicity. To overcome the limitation in the use of CDDP in the treatment of GBM patients, fourth generation platinum compounds are been synthesized, one of them is the Pt(IV)Ac-POA, a prodrug with a medium-chain fatty acid as axial ligand, which acts as a histone 3 deacetylase inhibitor. Moreover, recently, the antioxidant effects of medicinal mushrooms have been shown to induce a lowering of the toxicity of chemotherapy drugs, inducing greater therapeutic efficiency, thus the combined therapy of chemotherapy and micotherapy could be helpful in the treatment of GBM reducing the adverse effects of the former thanks to phytotherapy's antioxidant, anti-inflammatory, immunomodulatory and antitumoral activities. Here, through immunoblotting, ultrastructural and immunofluorescence analysis, we evaluated the contribution in the activation of different cell death pathway of Micotherapy U-Care, a medicinal blend supplement, used together with platinum-based compounds on human glioblastoma U251 cells.
Collapse
Affiliation(s)
- Ludovica Gaiaschi
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.
| | - Cristina Favaron
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| | - Claudio Casali
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| | - Federica Gola
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| | - Fabrizio De Luca
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| | - Mauro Ravera
- Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale "A. Avogadro", Viale Teresa Michel 11, 15121, Alessandria, Italy
| | - Elisa Roda
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
- Laboratory of Clinical and Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, ICS Maugeri Spa, IRCCS Pavia, Via Maugeri 10, Pavia, Italy
| | - Paola Rossi
- Laboratory of Neurophysiology and Integrated Physiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| | - Maria Grazia Bottone
- Laboratory of Cell Biology and Neurobiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Via Ferrata 9, 27100, Pavia, Italy
| |
Collapse
|
5
|
Mohapatra A, Mondal J, Sathiyamoorthy P, Mohanty A, Revuri V, Rajendrakumar SK, Lee YK, Park IK. Thermosusceptible Nitric-Oxide-Releasing Nitrogel for Strengthening Antitumor Immune Responses with Tumor Collagen Diminution and Deep Tissue Delivery during NIR Laser-Assisted Photoimmunotherapy. ACS APPLIED MATERIALS & INTERFACES 2023. [PMID: 36896475 DOI: 10.1021/acsami.3c01896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Combined cancer immunotherapy has demonstrated promising potential with an amplified antitumor response and immunosuppressive tumor microenvironment (TME) modulation. However, one of the main issues that cause treatment failure is the poor diffusion and insufficient penetration of therapeutic and immunomodulatory agents in solid tumors. Herein, a cancer treatment approach that combines photothermal therapy (PTT) and nitric oxide (NO) gas therapy for tumor extracellular matrix (ECM) degradation, along with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor that reduces tryptophan catabolism to kynurenine, and DMXAA, a stimulator of interferon gene (STING) agonist that stimulates antigen cross-presentation, is proposed to overcome this issue. Upon NIR (808 nm) laser irradiation, NO-GEL achieved the desired thermal ablation by releasing sufficient tumor antigens through immunogenic cell death (ICD). NO delivery triggered local diffusion of excess NO gas for effectively degrading tumor collagen in the ECM, homogeneously delivered NLG919 throughout the tumor tissue, inhibited IDO expression that was upregulated by PTT, and reduced the immune suppressive activities. The sustained release of DMXAA prolonged dendritic cell maturation and CD8+ T cell activation against the tumor. In summary, NO-GEL therapeutics offer a significant tumor regression with PTT and STING agonist combination that stimulates a durable antitumor immune response. Additional unification of IDO inhibition during PTT supplements the immunotherapy by reducing the T cell apoptosis and immune suppressive cell infiltration to TME. NO-GEL with the STING agonist and IDO inhibitor is an effective therapeutic combination to counter possible limitations during solid tumor immunotherapy.
Collapse
Affiliation(s)
- Adityanarayan Mohapatra
- Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju 61469, South Korea
| | - Jagannath Mondal
- Department of Green Bioengineering, Korea National University of Transportation, Chungju 27469, Republic of Korea
| | - Padmanaban Sathiyamoorthy
- Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju 61469, South Korea
| | - Ayeskanta Mohanty
- Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju 61469, South Korea
| | - Vishnu Revuri
- Department of Green Bioengineering, Korea National University of Transportation, Chungju 27469, Republic of Korea
| | | | - Yong-Kyu Lee
- Department of Green Bioengineering, Korea National University of Transportation, Chungju 27469, Republic of Korea
| | - In-Kyu Park
- Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju 61469, South Korea
| |
Collapse
|
6
|
De Luca F, Roda E, Ratto D, Desiderio A, Venuti MT, Ramieri M, Bottone MG, Savino E, Rossi P. Fighting secondary triple-negative breast cancer in cerebellum: A powerful aid from a medicinal mushrooms blend. Biomed Pharmacother 2023; 159:114262. [PMID: 36657301 DOI: 10.1016/j.biopha.2023.114262] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Revised: 01/05/2023] [Accepted: 01/14/2023] [Indexed: 01/18/2023] Open
Abstract
Breast cancer (BC) is the second most common cause of brain metastasis onset in patients, with the cerebellum accounting for the 33% of cases. In the current study, using a 4T1 triple-negative mouse BC model, we revealed that an orally administered medicinal mushrooms (MM) blend, rich in β-glucans, played a direct and specific anti-cancer action on cerebellar metastases, also bettering locomotor performances. The neuroprotective effect of the MM blend plays through (i) a direct and specific inhibition of cerebellar metastatization pattern typical of TNBC (with an induced reduction of about 50% of metastases density) and (ii) the regulation of apoptosis and proliferation-related genes, as suggested by expression changes of specific molecular markers, i.e. PCNA, p53, Bcl2, BAX, CASP9, CASP3, Hsp70 and AIF. Therefore, inhibiting the metastatization process, triggering a significant apoptosis increase, and lessening cell proliferation, this MM supplement, employed as adjuvant treatment in association with conventional therapy, could represent a promising approach, in the field of Integrative Oncology, for patients' management in both prevention and treatment of brain metastases from BC.
Collapse
Affiliation(s)
- Fabrizio De Luca
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| | - Elisa Roda
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy.
| | - Daniela Ratto
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| | - Anthea Desiderio
- Department of Earth and Environmental Science, University of Pavia, 27100 Pavia, Italy.
| | - Maria Teresa Venuti
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| | - Martino Ramieri
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| | - Maria Grazia Bottone
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| | - Elena Savino
- Department of Earth and Environmental Science, University of Pavia, 27100 Pavia, Italy.
| | - Paola Rossi
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
| |
Collapse
|
7
|
Wong GL, Manore SG, Doheny DL, Lo HW. STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Semin Cancer Biol 2022; 86:84-106. [PMID: 35995341 PMCID: PMC9714692 DOI: 10.1016/j.semcancer.2022.08.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 08/08/2022] [Accepted: 08/10/2022] [Indexed: 02/07/2023]
Abstract
Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic resistance contributing to tumor relapse. Through activating genes important for BCSCs, transcription factors contribute to breast cancer metastasis and therapeutic resistance, including the signal transducer and activator of transcription (STAT) family of transcription factors. The STAT family consists of six major isoforms, STAT1, STAT2, STAT3, STAT4, STAT5, and STAT6. Canonical STAT signaling is activated by the binding of an extracellular ligand to a cell-surface receptor followed by STAT phosphorylation, leading to STAT nuclear translocation and transactivation of target genes. It is important to note that STAT transcription factors exhibit diverse effects in breast cancer; some are either pro- or anti-tumorigenic while others maintain dual, context-dependent roles. Among the STAT transcription factors, STAT3 is the most widely studied STAT protein in breast cancer for its critical roles in promoting BCSCs, breast cancer cell proliferation, invasion, angiogenesis, metastasis, and immune evasion. Consequently, there have been substantial efforts in developing cancer therapeutics to target breast cancer with dysregulated STAT3 signaling. In this comprehensive review, we will summarize the diverse roles that each STAT family member plays in breast cancer pathobiology, as well as, the opportunities and challenges in pharmacologically targeting STAT proteins and their upstream activators in the context of breast cancer treatment.
Collapse
Affiliation(s)
- Grace L Wong
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Sara G Manore
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Daniel L Doheny
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Hui-Wen Lo
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Breast Cancer Center of Excellence, Wake Forest University School of Medicine, Winston-Salem, NC, USA; Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
| |
Collapse
|
8
|
The power of a novel combined anticancer therapy: challenge and opportunity of micotherapy in the treatment of Glioblastoma Multiforme. Biomed Pharmacother 2022; 155:113729. [PMID: 36166961 DOI: 10.1016/j.biopha.2022.113729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 09/13/2022] [Accepted: 09/19/2022] [Indexed: 11/21/2022] Open
Abstract
Glioblastoma (GBM) is the most common and mortal primary brain tumor in human. After standard therapies, that include surgical resection followed by radiotherapy and chemotherapy, it is difficult to completely remove the tumor and the development of relapses and resistance is almost inevitable. The chemotherapy now available also show important side effects, to overcame those limitation, new platinum-based drugs are being synthetized, Pt(IV)Ac-POA, (OC-6-44)-acetate-diamine-chloride(2-(2-propynyl)octanoato)platinum(IV), a prodrug having an Histone-3-DeAcetylase-Inhibitor as axial ligands, is one of them. Moreover, new compounds of plant origin are increasingly seen as potential sources of benefits in oncological treatments. The aim of the study is to investigate the possible contribution of micotherapy in the fight against GBM, its role in the metabolism of reactive oxygen species (ROS) and its synergic effect with a new platinum-based compound, Pt(IV)Ac-POA, on human glioblastoma U251 cells. Through cytofluorimetric and immunofluorescence analysis, the ability of the micotherapy in study to regulate the cell cycle was assessed, and its importance in controlling the cellular redox state was also revealed, opening to the possibility of a new therapy in which micotherapy can support the activity of new chemotherapy while reducing its side effects controlling inflammatory conditions in the microenvironment. Additionally, the combined therapy appeared able to induce regulated form of necrosis, such as ferroptosis, and to hinder the establishment of resistance mechanisms.
Collapse
|
9
|
Boulaka A, Mantellou P, Stanc GM, Souka E, Valavanis C, Saxami G, Mitsou E, Koutrotsios G, Zervakis GI, Kyriacou A, Pletsa V, Georgiadis P. Genoprotective activity of the Pleurotus eryngii mushrooms following their in vitro and in vivo fermentation by fecal microbiota. Front Nutr 2022; 9:988517. [PMID: 36082029 PMCID: PMC9445615 DOI: 10.3389/fnut.2022.988517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 08/08/2022] [Indexed: 11/19/2022] Open
Abstract
Pleurotus eryngii mushrooms are commercially cultivated and widely consumed due to their organoleptic properties, and the low caloric and high nutritional value. In addition, they contain various biologically active and health-promoting compounds; very recently, their genoprotective effect in Caco-2 cells after their fermentation by the human fecal microbiota was also documented. In the current study, the effect of P. eryngii pre- and post-fermentation supernatants in micronuclei formation was evaluated in human lymphocytes. In addition, the genoprotective properties of increasing concentrations of aqueous extracts from P. eryngii mushrooms (150, 300, 600 mg/kg) against the cyclophosphamide-induced DNA damage were studied in young and elderly female and male mice in bone marrow and whole blood cells. The ability of the highest dose (600 mg/kg) to regulate the main cellular signaling pathways was also evaluated in gut and liver tissues of female animals by quantifying the mRNA expression of NrF2, Nfkβ, DNMT1, and IL-22 genes. P. eryngii post-fermentation, but not pre-fermentation, supernatants were able to protect human lymphocytes from the mitomycin C-induced DNA damage in a dose-dependent manner. Similarly, genoprotection was also observed in bone marrow cells of mice treated by gavage with P. eryngii extract. The effect was observed in all the experimental groups of mice (young and elderly, male and female) and was more potent in young female mice. Overexpression of all genes examined was observed in both tissues, mainly among the elderly animals. In conclusion, P. eryngii mushrooms were shown to maintain genome integrity through protecting cells from genotoxic insults. These beneficial effects can be attributed to their antioxidant and immunomodulatory properties, as well as their ability to regulate the cell’s epigenetic mechanisms and maintain cell homeostasis.
Collapse
Affiliation(s)
- Athina Boulaka
- Laboratory of Environment and Health, Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece
| | - Panagiota Mantellou
- Laboratory of Environment and Health, Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece
- Department of Biological Applications and Technology, University of Ioannina, Ioannina, Greece
| | - Gabriela-Monica Stanc
- Department of Pathology, Molecular Pathology Unit, Metaxa Cancer Hospital, Piraeus, Greece
| | - Efthymia Souka
- Department of Pathology, Molecular Pathology Unit, Metaxa Cancer Hospital, Piraeus, Greece
| | - Christoς Valavanis
- Department of Pathology, Molecular Pathology Unit, Metaxa Cancer Hospital, Piraeus, Greece
| | - Georgia Saxami
- Department of Nutrition and Dietetics, Harokopio University, Athens, Greece
| | - Evdokia Mitsou
- Department of Nutrition and Dietetics, Harokopio University, Athens, Greece
| | - Georgios Koutrotsios
- Laboratory of General and Agricultural Microbiology, Agricultural University of Athens, Athens, Greece
| | - Georgios I. Zervakis
- Laboratory of General and Agricultural Microbiology, Agricultural University of Athens, Athens, Greece
| | | | - Vasiliki Pletsa
- Laboratory of Environment and Health, Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece
| | - Panagiotis Georgiadis
- Laboratory of Environment and Health, Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece
- *Correspondence: Panagiotis Georgiadis,
| |
Collapse
|
10
|
Berretta M, Morra A, Taibi R, Monari F, Maurea N, Ippolito M, Tirelli U, Fiorica F, Montella L, Facchini G, Quagliariello V, Montopoli M. Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature. Front Pharmacol 2022; 13:867907. [PMID: 35784762 PMCID: PMC9243589 DOI: 10.3389/fphar.2022.867907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 05/03/2022] [Indexed: 12/18/2022] Open
Abstract
Objectives: According to the National Cancer Institute, the integrative medicine (IM) approach to medical care combines standard medicine with complementary and alternative medicine practices that have proved safe and effective.Methods: We describe the clinical cases of four patients with malignant pleural mesothelioma (MPM), diffuse malignant peritoneal mesothelioma (DMPM), intrahepatic cholangiocarcinoma, and breast cancer (BC) who received supportive treatment (ST) according to an IM approach after the failure of standard cancer treatments or the appearance of serious adverse events caused by antiblastic chemotherapy. The critical role of complementary drugs in reducing the side effects of cancer treatments and normalizing the white cell count is especially apparent in the case of the patient with metastatic BC, who experienced prolonged neutropenia.Results: The IM approach was well-tolerated and had no adverse side effects. It improved the quality of life (QoL) of all patients and in two cases extended overall survival.Conclusion: The extended clinical and instrumental response to IM of the patients with malignant mesothelioma and the improved health-related QoL and good tolerance of the ST demonstrated in all cases support the value of this approach in patients whose cancer therapies have failed but who show a good performance status. Our data require confirmation in a well-designed prospective clinical trial.
Collapse
Affiliation(s)
- M. Berretta
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
- Integrative Medicine Research Group, IMRG, Noceto, Italy
- *Correspondence: M. Berretta,
| | - A. Morra
- IRCCS SDN, SYNLAB Napoli, Naples, Italy
| | - R. Taibi
- Gruppo Oncologico Ricercatori Italiani, GORI-Onlus, Pordenone, Italy
| | - F. Monari
- Radiotherapy Unit, Policlinico Di Sant'Orsola, University of Bologna, Bologna, Italy
| | - N. Maurea
- Division of Cardiology, Istituto Nazionale Tumori, Naples, Italy
| | - M. Ippolito
- Department of Advanced Technologies, Nuclear Medicine and PET, “Cannizzaro” Hospital, Catania, Italy
| | - U. Tirelli
- Tirelli Medical Center, Pordenone, Italy
| | - F. Fiorica
- Department of Radiation Oncology and Nuclear Medicine, Verona, Italy
| | - L. Montella
- ASL NA2 NORD, Oncology Operative Unit, “Santa Maria Delle Grazie” Hospital, Naples, Italy
| | - G. Facchini
- ASL NA2 NORD, Oncology Operative Unit, “Santa Maria Delle Grazie” Hospital, Naples, Italy
| | - V. Quagliariello
- Division of Cardiology, Istituto Nazionale Tumori, Naples, Italy
| | - M. Montopoli
- Integrative Medicine Research Group, IMRG, Noceto, Italy
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| |
Collapse
|
11
|
Yin M, Hu J, Yuan Z, Luo G, Yao J, Wang R, Liu D, Cao B, Wu W, Hu Z. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway. Cell Cycle 2022; 21:767-779. [PMID: 35130108 PMCID: PMC8973354 DOI: 10.1080/15384101.2022.2029996] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
This study aimed to explore the role of a stimulator of interferon (IFN) gene (STING) agonist in breast cancer (BCa) immunotherapy. Clinical samples were collected from 37 patients with BCa. A tumor-bearing mouse model was established by injecting 4T1 cells into the mammary fat pad of mice. STING agonist and atezolizumab were injected in the mice twice a week for 2 weeks. Peripheral blood, tumor mass, lung, liver, brain cortex and kidney samples of the tumor-bearing mice were collected. Anti-IFN alpha receptor subunit 1 (IFNAR1) was used to treat 4T1 cells. Tumor tissues of patients with BCa exhibited lower STING and high programmed cell death protein 1 and programmed death-ligand 1 protein expressions. The STING agonist inhibited 4T1 cell growth in mice (P < 0.001) and increased the IFN-β level and phosphorylation of STING, TBK1, IRF3 and STAT1 in tumor mass of tumor-bearing mice (P < 0.001). It synergized with atezolizumab to inhibit 4T1 cell growth in mice and increased tumor necrosis factor-α, IFN-β, interleukin-10 and IFN-γ levels in the peripheral blood and tumor mass (P < 0.01). It synergized with atezolizumab to increase CD8+ cytotoxic T cells and decrease FOXP3+ Treg cells in the tumor-bearing mouse model. The STING agonist was nontoxic to the lung, liver, brain cortex and kidney. Anti-IFNAR1 reversed the STING agonist promotion on TBK1, IRF3 and STAT1 phosphorylation in 4T1 cells (P < 0.01). STING agonists enhance the efficacy of atezolizumab in BCa immunotherapy by activating the IFN-β signaling pathway.
Collapse
Affiliation(s)
- Mingming Yin
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Jinlong Hu
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Zhongxu Yuan
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Guangyi Luo
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Jiaming Yao
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Rundong Wang
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Dongquan Liu
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Baoqiang Cao
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University
| | - Wenyong Wu
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University,CONTACT Wenyong Wu
| | - Zhiqi Hu
- Department of General Surgery, Anhui No. 2 Provincial People’s Hospital, Anhui Medical University, Hefei, Anhui Province, China,The Fifth Clinical Medical College of Anhui Medical University,Zhiqi Hu Department of General Surgery, Anhui No.2 Provincial People’s Hospital, No.1868 Dangshan Road, Yaohai District, Hefei, Anhui Province, 230041, China. +86-0551-64270331
| |
Collapse
|
12
|
Cartabia M, Girometta CE, Milanese C, Baiguera RM, Buratti S, Branciforti DS, Vadivel D, Girella A, Babbini S, Savino E, Dondi D. Collection and Characterization of Wood Decay Fungal Strains for Developing Pure Mycelium Mats. J Fungi (Basel) 2021; 7:1008. [PMID: 34946991 PMCID: PMC8703653 DOI: 10.3390/jof7121008] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 11/19/2021] [Accepted: 11/22/2021] [Indexed: 12/26/2022] Open
Abstract
Wood decay fungi (WDF) seem to be particularly suitable for developing myco-materials due to their mycelial texture, ease of cultivation, and lack of sporification. This study focused on a collection of WDF strains that were later used to develop mycelium mats of leather-like materials. Twenty-one WDF strains were chosen based on the color, homogeneity, and consistency of the mycelia. The growth rate of each strain was measured. To improve the consistency and thickness of the mats, an exclusive method (newly patented) was developed. The obtained materials and the corresponding pure mycelia grown in liquid culture were analyzed by both thermogravimetric analysis (TGA) and scanning electron microscopy (SEM) to evaluate the principal components and texture. TGA provided a semi-quantitative indication on the mycelia and mat composition, but it was hardly able to discriminate differences in the production process (liquid culture versus patented method). SEM provided keen insight on the mycelial microstructure as well as that of the mat without considering the composition; however, it was able to determine the hyphae and porosity dimensions. Although not exhaustive, TGA and SEM are complementary methods that can be used to characterize fungal strains based on their desirable features for various applications in bio-based materials. Taking all of the results into account, the Fomitopsis iberica strain seems to be the most suitable for the development of leather-like materials.
Collapse
Affiliation(s)
- Marco Cartabia
- Department of Earth and Environmental Sciences, University of Pavia, 27100 Pavia, Italy; (M.C.); (R.M.B.); (S.B.); (E.S.)
- MOGU S.r.l., Via S. Francesco 62, 21020 Inarzo, Italy;
| | - Carolina Elena Girometta
- Department of Earth and Environmental Sciences, University of Pavia, 27100 Pavia, Italy; (M.C.); (R.M.B.); (S.B.); (E.S.)
| | - Chiara Milanese
- Department of Chemistry, University of Pavia, 27100 Pavia, Italy; (C.M.); (D.S.B.); (D.V.); (A.G.); (D.D.)
| | - Rebecca Michela Baiguera
- Department of Earth and Environmental Sciences, University of Pavia, 27100 Pavia, Italy; (M.C.); (R.M.B.); (S.B.); (E.S.)
| | - Simone Buratti
- Department of Earth and Environmental Sciences, University of Pavia, 27100 Pavia, Italy; (M.C.); (R.M.B.); (S.B.); (E.S.)
| | - Diego Savio Branciforti
- Department of Chemistry, University of Pavia, 27100 Pavia, Italy; (C.M.); (D.S.B.); (D.V.); (A.G.); (D.D.)
| | - Dhanalakshmi Vadivel
- Department of Chemistry, University of Pavia, 27100 Pavia, Italy; (C.M.); (D.S.B.); (D.V.); (A.G.); (D.D.)
| | - Alessandro Girella
- Department of Chemistry, University of Pavia, 27100 Pavia, Italy; (C.M.); (D.S.B.); (D.V.); (A.G.); (D.D.)
| | | | - Elena Savino
- Department of Earth and Environmental Sciences, University of Pavia, 27100 Pavia, Italy; (M.C.); (R.M.B.); (S.B.); (E.S.)
| | - Daniele Dondi
- Department of Chemistry, University of Pavia, 27100 Pavia, Italy; (C.M.); (D.S.B.); (D.V.); (A.G.); (D.D.)
| |
Collapse
|
13
|
Yadav D, Negi PS. Bioactive components of mushrooms: Processing effects and health benefits. Food Res Int 2021; 148:110599. [PMID: 34507744 DOI: 10.1016/j.foodres.2021.110599] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 07/04/2021] [Accepted: 07/07/2021] [Indexed: 02/07/2023]
Abstract
Mushrooms have been recognized for their culinary attributes for long and were relished in the most influential civilizations in history. Currently, they are the focus of renewed research because of their therapeutic abilities. Nutritional benefits from mushrooms are in the form of a significant source of essential proteins, dietary non-digestible carbohydrates, unsaturated fats, minerals, as well as various vitamins, which have enhanced its consumption, and also resulted in the development of various processed mushroom products. Mushrooms are also a crucial ingredient in traditional medicine for their healing potential and curative properties. The literature on the nutritional, nutraceutical, and therapeutic potential of mushrooms, and their use as functional foods for the maintenance of health was reviewed, and the available literature indicates the enormous potential of the bioactive compounds present in mushrooms. Future research should be focused on the development of processes to retain the mushroom bioactive components, and valorization of waste generated during processing. Further, the mechanisms of action of mushroom bioactive components should be studied in detail to delineate their diverse roles and functions in the prevention and treatment of several diseases.
Collapse
Affiliation(s)
- Divya Yadav
- Department of Fruit and Vegetables Technology, CSIR-Central Food Technological Research Institute, Mysuru 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India
| | - Pradeep Singh Negi
- Department of Fruit and Vegetables Technology, CSIR-Central Food Technological Research Institute, Mysuru 570020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, India.
| |
Collapse
|
14
|
Balakrishnan B, Liang Q, Fenix K, Tamang B, Hauben E, Ma L, Zhang W. Combining the Anticancer and Immunomodulatory Effects of Astragalus and Shiitake as an Integrated Therapeutic Approach. Nutrients 2021; 13:nu13082564. [PMID: 34444724 PMCID: PMC8401741 DOI: 10.3390/nu13082564] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 07/13/2021] [Accepted: 07/21/2021] [Indexed: 12/21/2022] Open
Abstract
Astragalus root (Huang Qi) and Shiitake mushrooms (Lentinus edodes) are both considered medicinal foods and are frequently used in traditional Chinese medicine due to their anticancer and immunomodulating properties. Here, the scientific literatures describing evidence for the anticancer and immunogenic properties of Shiitake and Astragalus were reviewed. Based on our experimental data, the potential to develop medicinal food with combined bioactivities was assessed using Shiitake mushrooms grown over Astragalus beds in a proprietary manufacturing process, as a novel cancer prevention approach. Notably, our data suggest that this new manufacturing process can result in transfer and increased bioavailability of Astragalus polysaccharides with therapeutic potential into edible Shiitake. Further research efforts are required to validate the therapeutic potential of this new Hengshan Astragalus Shiitake medicinal food.
Collapse
Affiliation(s)
- Biju Balakrishnan
- Centre for Marine Bioproducts Development, College of Medicine & Public Health, Flinders University, Bedford Park, Adelaide, SA 5042, Australia; (B.B.); (Q.L.); (B.T.)
- The Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia;
| | - Qi Liang
- Centre for Marine Bioproducts Development, College of Medicine & Public Health, Flinders University, Bedford Park, Adelaide, SA 5042, Australia; (B.B.); (Q.L.); (B.T.)
- Shanxi University of Traditional Chinese Medicine, Taiyuan 030600, China
| | - Kevin Fenix
- The Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia;
- Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia
| | - Bunu Tamang
- Centre for Marine Bioproducts Development, College of Medicine & Public Health, Flinders University, Bedford Park, Adelaide, SA 5042, Australia; (B.B.); (Q.L.); (B.T.)
| | - Ehud Hauben
- The Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5011, Australia;
- Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia
- AusHealth Corporate Pty Ltd., Adelaide, SA 5032, Australia
- Correspondence: (E.H.); (L.M.); (W.Z.); Tel.: +61-88132-7450 (E.H.); +61-7-3735-4175 (L.M.); +61-8-7221-8557 (W.Z.)
| | - Linlin Ma
- Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia
- Correspondence: (E.H.); (L.M.); (W.Z.); Tel.: +61-88132-7450 (E.H.); +61-7-3735-4175 (L.M.); +61-8-7221-8557 (W.Z.)
| | - Wei Zhang
- Centre for Marine Bioproducts Development, College of Medicine & Public Health, Flinders University, Bedford Park, Adelaide, SA 5042, Australia; (B.B.); (Q.L.); (B.T.)
- Correspondence: (E.H.); (L.M.); (W.Z.); Tel.: +61-88132-7450 (E.H.); +61-7-3735-4175 (L.M.); +61-8-7221-8557 (W.Z.)
| |
Collapse
|
15
|
Yasin HK, Taylor AH, Ayakannu T. A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer. Cancers (Basel) 2021; 13:cancers13092149. [PMID: 33946913 PMCID: PMC8125712 DOI: 10.3390/cancers13092149] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Revised: 04/12/2021] [Accepted: 04/16/2021] [Indexed: 12/19/2022] Open
Abstract
Simple Summary The incidence and prevalence of endometrial cancer is increasing globally. The main factors involved in this increase have been the way women live today and what they eat and drink. In fact, the obesity pandemic that is sweeping across the planet is considered to be the main contributory feature. This review aims to introduce to a new audience, those that are not experts in the field, what is known about the different types of endometrial cancer and the mechanisms for their induction and protection. We also seek to summarise the existing knowledge on dietary and lifestyle factors that prevent endometrial development in susceptible populations and identify the main problem in this arena; the paucity of research studies and clinical trials that investigate the interaction(s) between diet, lifestyle and endometrial cancer risk whilst highlighting those areas of promise that should be further investigated. Abstract Endometrial cancer is the most common cancer affecting the reproductive organs of women living in higher-income countries. Apart from hormonal influences and genetic predisposition, obesity and metabolic syndrome are increasingly recognised as major factors in endometrial cancer risk, due to changes in lifestyle and diet, whereby high glycaemic index and lipid deposition are prevalent. This is especially true in countries where micronutrients, such as vitamins and minerals are exchanged for high calorific diets and a sedentary lifestyle. In this review, we will survey the currently known lifestyle factors, dietary requirements and hormonal changes that increase an individual’s risk for endometrial cancer and discuss their relevance for clinical management. We also examine the evidence that everyday factors and clinical interventions have on reducing that risk, such that informed healthy choices can be made. In this narrative review, we thus summarise the dietary and lifestyle factors that promote and prevent the incidence of endometrial cancer.
Collapse
Affiliation(s)
- Hajar Ku Yasin
- Department of Obstetrics & Gynaecology, Cumberland Infirmary, Carlisle CA2 7HY, UK;
| | - Anthony H. Taylor
- Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 7RH, UK;
| | - Thangesweran Ayakannu
- Gynaecology Oncology Cancer Centre, Liverpool Women’s NHS Foundation Trust, Liverpool Women’s Hospital, Liverpool L8 7SS, UK
- Correspondence: ; Tel.: +44-(0)-151-708-9988 (ext. 4531)
| |
Collapse
|
16
|
Wan-Mohtar WAAQI, Ilham Z, Jamaludin AA, Rowan N. Use of Zebrafish Embryo Assay to Evaluate Toxicity and Safety of Bioreactor-Grown Exopolysaccharides and Endopolysaccharides from European Ganoderma applanatum Mycelium for Future Aquaculture Applications. Int J Mol Sci 2021; 22:1675. [PMID: 33562361 PMCID: PMC7914815 DOI: 10.3390/ijms22041675] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 01/30/2021] [Accepted: 02/04/2021] [Indexed: 12/15/2022] Open
Abstract
Natural mycelial exopolysaccharide (EPS) and endopolysaccharide (ENS) extracted from bioreactor-cultivated European Ganoderma applanatum mushrooms are of potential high commercial value for both food and adjacent biopharmaceutical industries. In order to evaluate their potential toxicity for aquaculture application, both EPS (0.01-10 mg/mL) and ENS (0.01-10 mg/mL) extracts were tested for Zebrafish Embryo Toxicity (ZFET); early development effects on Zebrafish Embryos (ZE) were also analyzed between 24 and 120 h post-fertilization (HPF). Both EPS and ENS are considered non-toxic with LC50 of 1.41 mg/mL and 0.87 mg/mL respectively. Both EPS and ENS did not delay hatching and teratogenic defect towards ZE with <1.0 mg/mL, respectively. No significant changes in the ZE heart rate were detected following treatment with the two compounds tested (EPS: 0.01-10 mg/mL: 176.44 ± 0.77 beats/min and ENS: 0.01-10 mg/mL: 148.44 ± 17.75 beats/min) compared to normal ZE (120-180 beats/min). These initial findings support future pre-clinical trials in adult fish models with view to safely using EPS and ENS as potential feed supplements for supplements for development of the aquaculture industry.
Collapse
Affiliation(s)
- Wan Abd Al Qadr Imad Wan-Mohtar
- Functional Omics and Bioprocess Development Laboratory, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia;
- Bioresources and Bioprocessing Research Group, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia;
- Bioscience Research Institute, Athlone Institute of Technology, Dublin Road, N37 WO89 Athlone, Westmeath, Ireland
| | - Zul Ilham
- Bioresources and Bioprocessing Research Group, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia;
- Environmental Science and Management Program, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia;
| | - Adi Ainurzaman Jamaludin
- Environmental Science and Management Program, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur 50603, Malaysia;
| | - Neil Rowan
- Bioscience Research Institute, Athlone Institute of Technology, Dublin Road, N37 WO89 Athlone, Westmeath, Ireland
- Empower Eco Innovation Hub, Lough Boora, Co., R35 DA50 Tullamore, Offaly, Ireland
| |
Collapse
|
17
|
Zeb M, Lee CH. Medicinal Properties and Bioactive Compounds from Wild Mushrooms Native to North America. Molecules 2021; 26:E251. [PMID: 33419035 PMCID: PMC7825331 DOI: 10.3390/molecules26020251] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 12/21/2020] [Accepted: 01/03/2021] [Indexed: 02/06/2023] Open
Abstract
Mushrooms, the fruiting bodies of fungi, are known for a long time in different cultures around the world to possess medicinal properties and are used to treat various human diseases. Mushrooms that are parts of traditional medicine in Asia had been extensively studied and this has led to identification of their bioactive ingredients. North America, while home to one of the world's largest and diverse ecological systems, has not subjected its natural resources especially its diverse array of mushroom species for bioprospecting purposes: Are mushrooms native to North America a good source for drug discovery? In this review, we compile all the published studies up to September 2020 on the bioprospecting of North American mushrooms. Out of the 79 species that have been investigated for medicinal properties, 48 species (60%) have bioactivities that have not been previously reported. For a mere 16 selected species, 17 new bioactive compounds (10 small molecules, six polysaccharides and one protein) have already been isolated. The results from our literature search suggest that mushrooms native to North America are indeed a good source for drug discovery.
Collapse
Affiliation(s)
| | - Chow H. Lee
- Chemistry and Biochemistry Program, University of Northern British Columbia, Prince George, BC V2N 4Z9, Canada;
| |
Collapse
|
18
|
Roda E, Luca FD, Locatelli CA, Ratto D, Di Iorio C, Savino E, Bottone MG, Rossi P. From a Medicinal Mushroom Blend a Direct Anticancer Effect on Triple-Negative Breast Cancer: A Preclinical Study on Lung Metastases. Molecules 2020; 25:molecules25225400. [PMID: 33218180 PMCID: PMC7699227 DOI: 10.3390/molecules25225400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 11/13/2020] [Accepted: 11/16/2020] [Indexed: 01/25/2023] Open
Abstract
Bioactive metabolites isolated from medicinal mushrooms (MM) used as supportive treatment in conventional oncology have recently gained interest. Acting as anticancer agents, they interfere with tumor cells and microenvironment (TME), disturbing cancer development/progression. Nonetheless, their action mechanisms still need to be elucidated. Recently, using a 4T1 triple-negative mouse BC model, we demonstrated that supplementation with Micotherapy U-Care, a MM blend, produced a striking reduction of lung metastases density/number, paralleled by decreased inflammation and oxidative stress both in TME and metastases, together with QoL amelioration. We hypothesized that these effects could be due to either a direct anticancer effect and/or to a secondary/indirect impact of Micotherapy U-Care on systemic inflammation/immunomodulation. To address this question, we presently focused on apoptosis/proliferation, investigating specific molecules, i.e., PARP1, p53, BAX, Bcl2, and PCNA, whose critical role in BC is well recognized. We revealed that Micotherapy U-Care is effective to influence balance between cell death and proliferation, which appeared strictly interconnected and inversely related (p53/Bax vs. Bcl2/PARP1/PCNA expression trends). MM blend displayed a direct effect, with different efficacy extent on cancer cells and TME, forcing tumor cells to apoptosis. Yet again, this study supports the potential of MM extracts, as adjuvant supplement in the TNBC management.
Collapse
Affiliation(s)
- Elisa Roda
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy;
- Correspondence: (E.R.); (P.R.); Tel.: +39-0382-5924-14 (E.R.); +39-0382-8960-76 (P.R.)
| | - Fabrizio De Luca
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
| | - Carlo Alessandro Locatelli
- Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy;
| | - Daniela Ratto
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
| | - Carmine Di Iorio
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
| | - Elena Savino
- Department of Earth and Environmental Science, University of Pavia, 27100 Pavia, Italy;
| | - Maria Grazia Bottone
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
| | - Paola Rossi
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy; (F.D.L.); (D.R.); (C.D.I.); (M.G.B.)
- Correspondence: (E.R.); (P.R.); Tel.: +39-0382-5924-14 (E.R.); +39-0382-8960-76 (P.R.)
| |
Collapse
|